18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer

Value of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography and Molecular Tumor Characterisation in Preoperative Staging og Postoperative Control of Colon Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01636674

Acronym

COLOPET1

Enrollment

Registered

2012-07-10

Start date

2009-07-31

Completion date

2013-03-31

Last updated

2012-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Keywords

positron emission tomography, computed tomography, fluordeoxyglucose, colon cancer, cancer, staging, imaging

Brief summary

The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer. Furthermore, the investigators combine 18F-FDG PET findings with clinical and histopathological features, circulating tumor cell (CTC) analyses, tumor gene expression and measurements of circulating cancer biomarkers sUPAR, TIMP-1 and CEA in order to predict tumor recurrence. The investigators hypothesis: The combination of functional imaging by 18F-FDG PET/CT and pre-existing and evolving molecular biomarkers will optimize tumor characterization, staging of disease and early detection of recurrence.

Interventions

OTHER18F-fluordeoxyglucose positron emission tomography/ computed tomography

18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* clinical or histological diagnosis of malignant clonic neoplasm (distance of more than 15 cm from anal ring) * 18 years of age or older * written informed consent

Exclusion criteria

* diabetes * known malignant disease other than colon cancer * known metastatic disease * impairment of renal function * allergy to CT contrast agents * body weight of more than 150 kg * claustrophobia

Design outcomes

Primary

Measure	Time frame
time to recurrence	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026